Eton Pharmaceuticals acquires rights to autoinjector
DEER PARK -- Eton Pharmaceuticals Inc. said it has acquired U.S. and Canadian rights to Crossject's Zeneo hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.
"The Zeneo autoinjector is a revolutionary delivery system, and this product is a terrific strategic fit with our current adrenal insufficiency business," said Eton CEO Sean Brynjelsen.
Terms of the transaction were not disclosed.
The challenge for patients and caregivers facing an adrenal crisis is serious; an easy-to-use needleless autoinjector of hydrocortisone will be a game changer for Eton patients, the company said.
Eton expects to submit a new drug application for the product to the U.S. Food and Drug Administration in 2023. In the United States, it is estimated that approximately 100,000 patients currently suffer from adrenocortical insufficiency and are at risk for adrenal crisis.